Published in Physician Law Weekly, September 8th, 2004
Kineret could be an excellent alternative when an anti-TNF therapy provides an inadequate response. The agreement accelerates the creation of a sales and marketing organization by NPS in preparation for launching the company's investigational drug candidate, PREOS, which is being studied for the treatment of osteoporosis.
It also provides dedicated promotional support for Kineret, creating a mutually beneficial arrangement for NPS and Amgen on the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly